| 2.68 -0.01 (-0.37%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.58 | 1-year : | 4.18 |
| Resists | First : | 3.06 | Second : | 3.58 |
| Pivot price | 2.31 |
|||
| Supports | First : | 2.18 |
Second : | 1.63 |
| MAs | MA(5) : | 2.45 |
MA(20) : | 2.31 |
| MA(100) : | 1.55 |
MA(250) : | 1.87 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 89.6 |
D(3) : | 73.7 |
| RSI | RSI(14): 66.2 | |||
| 52-week | High : | 3.06 | Low : | 0.81 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MAIA ] has closed below upper band by 11.2%. Bollinger Bands are 58.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.72 - 2.73 | 2.73 - 2.74 |
| Low: | 2.37 - 2.38 | 2.38 - 2.39 |
| Close: | 2.67 - 2.69 | 2.69 - 2.7 |
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
Tue, 23 Apr 2024
MAIA Biotechnology secures $1 million in private placement By Investing.com - Investing.com
Tue, 23 Apr 2024
MAIA Biotechnology Announces $1.00 Million Private Placement - Business Wire
Fri, 05 Apr 2024
MAIA Biotechnology to Present at Two Investor Conferences in April 2024 - Business Wire
Tue, 02 Apr 2024
MAIA Biotechnology Boosts CEO Jeffrey Himmelreich's Salary - TipRanks.com - TipRanks
Fri, 22 Mar 2024
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement - Yahoo Finance
Fri, 22 Mar 2024
MAIA Biotechnology at Risk of NYSE Delisting Over Equity Shortfalls - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 24.3 (%) |
| Held by Institutions | 1.8 (%) |
| Shares Short | 179 (K) |
| Shares Short P.Month | 302 (K) |
| EPS | -1.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -103.3 % |
| Return on Equity (ttm) | -243.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -1.87 |
| PEG Ratio | 0 |
| Price to Book value | 13.44 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|